Cyclin Box Structure of the P-TEFb Subunit Cyclin T1 Derived from a Fusion Complex with EIAV Tat

Journal of Molecular Biology

Volumn 370, Issue 5, 2007, Pages 826-836

  Anand, Kanchan ^a   Schulte, Antje ^b   Fujinaga, Koh ^c   Scheffzek, Klaus ^a   Geyer, Matthias ^b  

^a EUROPEAN MOLECULAR BIOLOGY LABORATORY   (Germany)

^b MAX PLANCK INSTITUTE OF MOLECULAR PHYSIOLOGY   (Germany)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

crystal structure; cyclin T1; P TEFb; Tat; transcription

Indexed keywords

CYCLIN DEPENDENT KINASE 9; CYCLIN T1; HYBRID PROTEIN; POSITIVE TRANSCRIPTION ELONGATION FACTOR B;

ARTICLE; CRYSTAL STRUCTURE; CRYSTALLOGRAPHY; EQUINE INFECTIOUS ANEMIA VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REGULATORY MECHANISM; TRANSACTIVATION; VIRUS TRANSCRIPTION; ZINC FINGER MOTIF;

EQUINE INFECTIOUS ANEMIA VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 34250196457     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2007.04.077     Document Type: Article

References (54)

1. Jones K.A., and Peterlin B.M. Control of RNA initiation and elongation at the HIV-1 promoter. Annu. Rev. Biochem. 63 (1994) 717-743
2. Wei P., Garber M.E., Fang S.M., Fischer W.H., and Jones K.A. A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell 92 (1998) 451-462
3. Garber M.E., Wei P., Kewal Ramani V.N., Mayall T. P., Herrmann C.H., and Rice A.P. The interaction between HIV-1 Tat and human cyclin T1 requires zinc and a critical cysteine residue that is not conserved in the murine CycT1 protein. Genes Dev. 12 (1998) 3512-3527
4. Murray A.W. Recycling the cell cycle: cyclins revisited. Cell 116 (2004) 221-234
5. Shilatifard A., Conaway R.C., and Conaway J.W. The RNA polymerase II elongation complex. Annu. Rev. Biochem. 72 (2003) 693-715
6. Saunders A., Core L.J., and Lis J.T. Breaking barriers to transcription elongation. Nature Rev. Mol. Cell Biol. 7 (2006) 557-567
7. Peterlin B.M., and Price D.H. Controlling the elongation phase of transcription with P-TEFb. Mol. Cell 23 (2006) 297-305
8. Jeffrey P.D., Russo A.A., Polyak K., Gibbs E., Hurwitz J., Massague J., and Pavletich N.P. Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. Nature 376 (1995) 313-320
9. Russo A.A., Jeffrey P.D., Patten A.K., Massague J., and Pavletich N.P. Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex. Nature 382 (1996) 325-331
10. Brown N.R., Noble M.E., Endicott J.A., and Johnson L.N. The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases. Nature Cell Biol. 1 (1999) 438-443
11. Schulze-Gahmen U., and Kim S.H. Structural basis for CDK6 activation by a virus-encoded cyclin. Nature Struct. Biol. 9 (2002) 177-181
12. Honda R., Lowe E.D., Dubinina E., Skamnaki V., Cook A., Brown N.R., and Johnson L.N. The structure of cyclin E1/CDK2: implications for CDK2 activation and CDK2-independent roles. EMBO J. 24 (2005) 452-463
13. Cheng K.Y., Noble M.E., Skamnaki V., Brown N.R., Lowe E.D., Kontogiannis L., et al. The role of the phospho-CDK2/cyclin A recruitment site in substrate recognition. J. Biol. Chem. 281 (2006) 23167-23179
14. Peng J., Zhu Y., Milton J.T., and Price D.H. Identification of multiple cyclin subunits of human P-TEFb. Genes Dev. 12 (1998) 755-762
15. Meinhart A., Kamenski T., Hoeppner S., Baumli S., and Cramer P. A structural perspective of CTD function. Genes Dev. 19 (2005) 1401-1415
16. Marshall N.F., Peng J., Xie Z., and Price D.H. Control of RNA polymerase II elongation potential by a novel carboxyl-terminal domain kinase. J. Biol. Chem. 271 (1996) 27176-27183
17. Wada T., Takagi T., Yamaguchi Y., Watanabe D., and Handa H. Evidence that P-TEFb alleviates the negative effect of DSIF on RNA polymerase II-dependent transcription in vitro. EMBO J. 17 (1998) 7395-7403
18. Garriga J., Bhattacharya S., Calbo J., Marshall R.M., Truongcao M., Haines D.S., and Grana X. CDK9 is constitutively expressed throughout the cell cycle, and its steady-state expression is independent of SKP2. Mol. Cell. Biol. 23 (2003) 5165-5173
19. Michels A.A., Nguyen V.T., Fraldi A., Labas V., Edwards M., Bonnet F., et al. MAQ1 and 7SK RNA interact with CDK9/cyclin T complexes in a transcription-dependent manner. Mol. Cell. Biol. 23 (2003) 4859-4869
20. Yik J.H., Chen R., Nishimura R., Jennings J.L., Link A.J., and Zhou Q. Inhibition of P-TEFb (CDK9/Cyclin T) kinase and RNA polymerase II transcription by the coordinated actions of HEXIM1 and 7SK snRNA. Mol. Cell 12 (2003) 971-982
21. Sano M., Abdellatif M., Oh H., Xie M., Bagella L., Giordano A., et al. Activation and function of cyclin T-Cdk9 (positive transcription elongation factor-b) in cardiac muscle-cell hypertrophy. Nature Med. 8 (2002) 1310-1317
22. Wittmann B.M., Fujinaga K., Deng H., Ogba N., and Montano M.M. The breast cell growth inhibitor, estrogen down regulated gene 1, modulates a novel functional interaction between estrogen receptor alpha and transcriptional elongation factor cyclin T1. Oncogene 24 (2005) 5576-5588
23. Karn J. Tackling Tat. J. Mol. Biol. 293 (1999) 235-254
24. Taube R., Fujinaga K., Wimmer J., Barboric M., and Peterlin B.M. Tat transactivation: a model for the regulation of eukaryotic transcriptional elongation. Virology 264 (1999) 245-253
25. Zhang J., Tamilarasu N., Hwang S., Garber M.E., Huq I., Jones K.A., and Rana T.M. HIV-1 TAR RNA enhances the interaction between Tat and cyclin T1. J. Biol. Chem. 275 (2000) 34314-34319
26. Kaehlcke K., Dorr A., Hetzer-Egger C., Kiermer V., Henklein P., Schnoelzer M., et al. Acetylation of Tat defines a cyclinT1-independent step in HIV transactivation. Mol. Cell 12 (2003) 167-176
27. Taube R., Fujinaga K., Irwin D., Wimmer J., Geyer M., and Peterlin B.M. Interactions between equine cyclin T1, Tat, and TAR are disrupted by a leucine-to-valine substitution found in human cyclin T1. J. Virol. 74 (2000) 892-898
28. Albrecht T.R., Lund L.H., and Garcia-Blanco M.A. Canine cyclin T1 rescues equine infectious anemia virus tat trans-activation in human cells. Virology 268 (2000) 7-11
29. Fujinaga K., Irwin D., Taube R., Zhang F., Geyer M., and Peterlin B.M. A minimal chimera of human cyclin T1 and Tat binds TAR and activates human immunodeficiency virus transcription in murine cells. J. Virol. 76 (2002) 12934-12939
30. Andersen G., Busso D., Poterszman A., Hwang J.R., Wurtz J.M., Ripp R., et al. The structure of cyclin H: common mode of kinase activation and specific features. EMBO J. 16 (1997) 958-967
31. Noble M.E., Endicott J.A., Brown N.R., and Johnson L.N. The cyclin box fold: protein recognition in cell-cycle and transcription control. Trends Biochem. Sci. 22 (1997) 482-487
32. Hoeppner S., Baumli S., and Cramer P. Structure of the mediator subunit cyclin C and its implications for CDK8 function. J. Mol. Biol. 350 (2005) 833-842
33. Baek K., Brown R.S., Birrane G., and Ladias J.A. Crystal structure of human Cyclin K, a positive regulator of cyclin-dependent kinase 9. J. Mol. Biol. 366 (2007) 563-573
34. Das C., Edgcomb S.P., Peteranderl R., Chen L., and Frankel A.D. Evidence for conformational flexibility in the Tat-TAR recognition motif of cyclin T1. Virology 318 (2004) 306-317
35. Richter S., Ping Y.H., and Rana T.M. TAR RNA loop: a scaffold for the assembly of a regulatory switch in HIV replication. Proc. Natl Acad. Sci. USA 99 (2005) 7928-7933
36. Bieniasz P.D., Grdina T.A., Bogerd H.P., and Cullen B.R. Recruitment of a protein complex containing Tat and cyclin T1 to TAR governs the species specificity of HIV-1 Tat. EMBO J. 17 (1998) 7056-7065
37. Fujinaga K., Taube R., Wimmer J., Cujec T.P., and Peterlin B.M. Interactions between human cyclin T, Tat, and the transactivation response element (TAR) are disrupted by a cysteine to tyrosine substitution found in mouse cyclin T. Proc. Natl Acad. Sci. USA 96 (1999) 1285-1290
38. Fujinaga K., Irwin D., Huang Y., Taube R., Kurosu T., and Peterlin B.M. Dynamics of human immunodeficiency virus transcription: P-TEFb phosphorylates RD and dissociates negative effectors from the transactivation response element. Mol. Cell. Biol. 24 (2004) 787-795
39. Shojania S., and O'Neil J.D. HIV-1 Tat is a natively unfolded protein: the solution conformation and dynamics of reduced HIV-1 Tat (1-72) by NMR spectroscopy. J. Biol. Chem. 281 (2006) 8347-8356
40. Taube R., Lin X., Irwin D., Fujinaga K., and Peterlin B. M. Interaction between P-TEFb and the C-terminal domain of RNA polymerase II activates transcriptional elongation from sites upstream or downstream of target genes. Mol. Cell. Biol. 22 (2002) 321-331
41. Schulte A., Czudnochowski N., Barboric M., Schonichen A., Blazek D., Peterlin B.M., and Geyer M. Identification of a cyclin T-binding domain in Hexim1 and biochemical analysis of its binding competition with HIV-1 Tat. J. Biol. Chem. 280 (2005) 24968-24977
42. Li Q., Price J.P., Byers S.A., Cheng D., Peng J., and Price D.H. Analysis of the large inactive P-TEFb complex indicates that it contains one 7SK molecule, a dimer of HEXIM1 or HEXIM2, and two P-TEFb molecules containing Cdk9 phosphorylated at threonine 186. J. Biol. Chem. 280 (2005) 28819-28826
43. Barboric M., Yik J.H., Czudnochowski N., Yang Z., Chen R., Contreras X., et al. Tat competes with HEXIM1 to increase the active pool of P-TEFb for HIV-1 transcription. Nucl. Acids Res. 35 (2007) 2003-2012
44. Egloff S., Van Herreweghe E., and Kiss T. Regulation of polymerase II transcription by 7SK snRNA: two distinct RNA elements direct P-TEFb and HEXIM1 binding. Mol. Cell. Biol. 26 (2006) 630-642
45. Murchie A.I., Davis B., Isel C., Afshar M., Drysdale M.J., Bower J., et al. Structure-based drug design targeting an inactive RNA conformation: exploiting the flexibility of HIV-1 TAR RNA. J. Mol. Biol. 336 (2004) 625-638
46. Schonichen A., Alexander M., Gasteier J.E., Cuesta F.E., Fackler O.T., and Geyer M. Biochemical characterization of the diaphanous autoregulatory interaction in the formin homology protein FHOD1. J. Biol. Chem. 281 (2006) 5084-5093
47. Kabsch W. Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants. J. Appl. Crystallog. 26 (1993) 795-800
48. Yeates T.O. Detecting and overcoming crystal twinning. Methods Enzymol. 276 (1997) 344-358
49. CCP4 Collaborative Computational Project number 4. Acta Crystallog. sect. D 50 (1994) 760-763
50. Storoni L.C., McCoy A.J., and Read R.J. Likelihood-enhanced fast rotation functions. Acta Crystallog sect. D 60 (2004) 432-438
51. Sheldrick G.M., and Schneider T.R. SHELXL: High-resolution refinement. Methods Enzymol. 277 (1997) 319-343
52. Emsley P., and Cowtan K. COOT: model-building tools for molecular graphics. Acta Crystallog. sect. D. 60 (2004) 2126-2132
53. Laskowski R.A., MacArthur M.W., Moss D.S., and Thornton J.M. PROCHECK: a program to check the stereochemical quality of protein structures. J. Appl. Crystallog. 26 (1993) 283-291
54. Diederichs K., and Karplus P.A. Improved R-factors for diffraction data analysis in macromolecular crystallography. Nature Struct. Biol. 4 (1997) 269-275